Article
Urology & Nephrology
Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, Roman Gulati, Elisa M. Ledet, Casey Morrison, Anh Le, Ryan Hausler, Jill Stopfer, Sophie Hyman, Wendy Kohlmann, Anne Naumer, Jennie Vagher, Samantha E. Greenberg, Lorraine Naylor, Mercy Laurino, Eric Q. Konnick, Brian H. Shirts, Saud H. AlDubayan, Eliezer M. Van Allen, Bastien Nguyen, Joseph Vijai, Wassim Abida, Maria Carlo, Marianne Dubard-Gault, Daniel J. Lee, Luke D. Maese, Diana Mandelker, Bruce Montgomery, Michael J. Morris, Piper Nicolosi, Robert L. Nussbaum, Lauren E. Schwartz, Zsofia Stadler, Judy E. Garber, Kenneth Offit, Joshua D. Schiffman, Peter S. Nelson, Oliver Sartor, Michael F. Walsh, Colin C. Pritchard
Summary: Complementary analysis of prostate cancer incidence in LFS males and gTP53 prevalence in prostate cancer cohorts suggests that gTP53 predisposes to aggressive prostate cancer. Prostate cancer should be considered as part of LFS screening protocols and TP53 should be considered in germline prostate cancer susceptibility testing.
Article
Multidisciplinary Sciences
William D. Dupont, Joan P. Breyer, Spenser H. Johnson, W. Dale Plummer, Jeffrey R. Smith
Summary: The study found that the G84E germline mutation of HOXB13 predisposes to prostate cancer, and multiple rare genetic variants in European-ancestry case-control study populations have significant effects on prostate cancer risk. Independent risk signals were mainly detected from specific variants within SKAP1 and HOXB13.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Yuyan Qian, Jianhu Wang, Wenbin wANG, Peng li, Zhenhao Zhao, Yuan Jiang, Dandan Huang, He Ren, Yang Yang, Zhongfan Zhao, Lei Zhang, Jiandan Shi, Mulin Jun, Wangee Li
Summary: Using fine-mapping analysis and functional annotation, we identified likely causal variants and their target genes in prostate cancer. We found 3,395 potential disease-causing variants and linked them to 487 target genes through functional annotation. The top-ranked SNP, rs10486567, was predicted to regulate the HOTTIP gene. Deletion of the enhancer associated with rs10486567 reduced invasive migration in prostate cancer cells, which was rescued by HOTTIP overexpression in enhancer-deficient cells. Furthermore, rs10486567 was found to regulate HOTTIP through allele-specific long-range chromatin interaction.
Review
Oncology
Ciara S. McNevin, Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott, Stephen Finn
Summary: Studies have shown that prostate cancer patients with BRCA2/BRCA1 genetic aberrations are more likely to have worse disease and prognosis. BRCA2 mutation confers the highest risk for prostate cancer in men (8.6 fold in men & LE;65 years). While BRCA genes have garnered significant research attention, their role in the clinical assessment and treatment of prostate cancer remains complex.
Article
Environmental Sciences
Lauren M. Hurwitz, Laura E. Beane Freeman, Gabriella Andreotti, Jonathan N. Hofmann, Christine G. Parks, Dale P. Sandler, Jay H. Lubin, Jia Liu, Kristine Jones, Sonja I. Berndt, Stella Koutros
Summary: The study found that there is an interaction between pesticides, specific organic compounds, and genetic variants in relation to prostate cancer risk. Farmers exposed to certain organophosphate and organochlorine insecticides have an increased risk of prostate cancer. Additionally, there is a suggestion of interaction between pesticides and genetic variants occurring in regions associated with DNA damage response and variants related to altered androgen receptor-driven transcriptional programs critical for prostate cancer.
ENVIRONMENTAL RESEARCH
(2023)
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Urology & Nephrology
Rebecca G. Philipson, Tahmineh Romero, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Daniel E. Spratt, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Michelle Braccioforte, Phuoc T. Tran, Santiago Martin, Rafael Martinez-Monge, Daniel J. Krauss, Eyad I. Abu-Isa, Luca Valle, Natalie Chong, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Todd McNutt, Theodore L. DeWeese, Ashley E. Ross, Jay P. Ciezki, Derya Tilki, R. Jeffrey Karnes, Eric A. Klein, Jeffrey J. Tosoian, Paul C. Boutros, Nicholas G. Nickols, Prashant Bhat, David Shabsovich, Jesus E. Juarez, Patrick A. Kupelian, Matthew B. Rettig, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Michael L. Steinberg, David Elashoff, Eric M. Horwitz, Rahul D. Tendulkar, Amar U. Kishan
Summary: Radiorecurrent high-risk prostate cancer is characterized by an aggressive natural history, with early clinical evidence of distant metastases after biochemical recurrence. Approximately 30% of patients ultimately die from prostate cancer, highlighting the importance of upfront risk assessment and prompt systemic evaluation upon recurrence.
Article
Oncology
Sylvie Clairefond, Veronique Ouellet, Benjamin Peant, Veronique Barres, Pierre I. Karakiewicz, Anne-Marie Mes-Masson, Fred Saad
Summary: The study showed that the specific protein expression patterns of ERBB family members are associated with an increased risk of prostate cancer progression and mortality, useful in predicting biochemical relapse, metastasis development, and cancer-specific mortality.
Article
Health Care Sciences & Services
Eleonora Cini Tesar, Ivana Mikolasevic, Iva Skocilic, Arnela Redjovic, Damir Vucinic, Jasna Marusic, Gordana Djordjevic
Summary: Prostate cancer (Pca) is a common malignant disease in men and a leading cause of death. Surgery and radiotherapy (RT) are standard treatments. However, radioresistant tumors limit the effectiveness of radiotherapy. This research created a numerical index based on biomarkers and clinico-pathological parameters to assess the risk of tumor progression. The scoring system successfully identified patients at significant risk for progression.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Urology & Nephrology
Burcu F. Darst, Xin Sheng, Rosalind A. Eeles, Zsofia Kote-Jarai, David V. Conti, Christopher A. Haiman
Summary: The study revealed that the risk of prostate cancer from rare variants could vary based on an individual's genetic profile of common risk variants. Therefore, to comprehensively assess genetic risk of prostate cancer, it is crucial to consider both rare and common variants.
Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Article
Oncology
Crystal S. S. Langlais, Rebecca E. E. Graff, Erin L. L. Van Blarigan, John M. M. Neuhaus, Janet E. E. Cowan, Jeanette M. M. Broering, Peter Carroll, Stacey A. A. Kenfield, June M. M. Chan
Summary: This study found that individual behaviors are associated with prostate cancer progression. Behavioral scores allow assessment of the combined impact of multiple behaviors. The 2015 score was not associated with prostate cancer progression or mortality, while the 2021 and WCRF/AICR scores were associated with prostate cancer progression and mortality.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Tommy Nyberg, Marc Tischkowitz, Antonis C. Antoniou
Summary: BRCA1 and BRCA2 pathogenic variants are associated with prostate cancer risk with varying relative risks reported. The heterogeneity in estimates may be influenced by factors such as age, family history, and study-level differences in ethnicity composition. Subgroup analyses suggest risks may be modified by age, ethnicity, and PV location within BRCA2 for future risk estimation studies.
BRITISH JOURNAL OF CANCER
(2022)
Review
Oncology
William Butler, Jiaoti Huang
Summary: Prostate cancer is associated with altered glycosylation structures, which play important roles in diagnosis and prognosis, as well as tumor survival and metastasis. Various glycosylation molecules such as galectins and glycolipids have been implicated in PCa progression and may serve as potential therapeutic targets.
FRONTIERS IN ONCOLOGY
(2021)
Article
Genetics & Heredity
Yifei Cheng, Yixuan Meng, Shuwei Li, Dongliang Cao, Shuai Ben, Chao Qin, Lixin Hua, Gong Cheng
Summary: This study systematically evaluated the association of SNPs in 21 cholesterol biosynthesis pathway genes with the risk of prostate cancer (PCa) and found that the T allele of rs67415672 in HMGCS1 is a significant protective allele of PCa. The expression of HMGCS1 was significantly decreased in PCa primary tumors compared to normal tissues, indicating that rs67415672 might be a possible functional susceptibility loci for PCa.
Article
Oncology
Peter Scherman, Ingvar Syk, Erik Holmberg, Peter Naredi, Magnus Rizell
Summary: This study analyzed data from a national cohort of patients treated for CRLM and found that ablation therapy had a significantly more negative impact on survival compared to surgical resection, suggesting that surgical resection should be prioritized. Factors such as age, acute surgery, complications, tumor size, and location also significantly impacted patient survival.
Article
Oncology
Mats Lambe, Annette Wigertz, Fredrik Sandin, Erik Holmberg, Susanne Amsler-Nordin, Therese M. -L. Andersson, David Pettersson
Article
Dentistry, Oral Surgery & Medicine
Magdalena Korytowska, Gabriela Schwab, Daniel Giglio, Jan-Michael Hirsch, Erik Holmberg, Goran Kjeller, Lars Sand, Mats Wallstrom, Jenny Ohman, Paulo Braz-Silva, Bengt Hasseus
Summary: This study found that surgical removal of oral leukoplakia results in a low risk of long-term post-surgical pain. However, leukoplakia located on the lateral side of the tongue and with dysplasia are more likely to be associated with pain.
ACTA ODONTOLOGICA SCANDINAVICA
(2021)
Article
Oncology
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Warnberg, Arne Ostman
Summary: This study reveals the potential of stromal PDGFRb expression as a biomarker for RT benefit in DCIS patients, suggesting that low PDGFRb expression is predictive of strong RT benefit for IBE risk reduction, while high PDGFRb expression is not significantly associated with risk reduction.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Anders Hogmo, Erik Holmberg, Hedda Haugen Cange, Johan Reizenstein, Johan Wennerberg, Martin Beran, Karin Soderkvist, Eva Hammerlid, Helena Sjodin, Lovisa Farnebo, Karl Sandstrom, Lalle Hammarstedt-Nordenvall, Katarina Zborayova, Eva Brun
Summary: This retrospective study analyzed the treatment and survival outcomes in Swedish patients with BOTSCC. The study found that adding chemotherapy to radiotherapy improved survival in patients with advanced p16+ tumors. However, for early-stage p16+ tumors, none of the treatment strategies was superior to radiotherapy alone. Brachytherapy showed no additional benefit in the overall treatment. Patients with p16- tumors had a poorer prognosis, but the small sample size prevented comparisons between different treatment strategies.
Article
Oncology
Janusz Marcickiewicz, Elisabeth Avall-Lundqvist, Erik Carl Viktor Holmberg, Christer Borgfeldt, Maria Bjurberg, Pernilla Dahm-Kahler, Angelique Floter-Radestad, Kristina Hellman, Thomas Hogberg, Per Rosenberg, Karin Stalberg, Preben Kjolhede
Summary: In this study, the association between wait time from diagnosis to surgery and survival in endometrial cancer patients was explored. It was found that undergoing surgery within the first two weeks after diagnosis was associated with worsened survival, while a prolonged wait time did not significantly affect prognosis. Factors such as age, tumor stage, histology, and risk group were highly associated with survival, whereas education and country of origin did not impact survival rates.
Article
Oncology
C. Chamalidou, H. Fohlin, P. Albertsson, L. -G. Arnesson, Z. Einbeigi, E. Holmberg, A. Nordenskjold, B. Nordenskjold, P. Karlsson, B. Linderholm
Summary: The study found that patients with invasive lobular carcinoma (ILC) had higher survival rates in the first five years after surgery compared to invasive ductal carcinoma (IDC), but in the 10-15 years after surgery, patients with ILC had a higher excess mortality rate ratio than those with IDC. After 20 years post-surgery, the relative survival rates for ILC and IDC were similar.
Article
Oncology
Julia Tutzauer, Martin Sjostrom, Erik Holmberg, Per Karlsson, Fredrika Killander, L. M. Fredrik Leeb-Lundberg, Per Malmstrom, Emma Nimeus, Marten Ferno, Annika Jogi
Summary: This study found that postoperative radiotherapy still benefits patients with hypoxic primary breast tumors. However, compared to patients with HIF-1 alpha-negative tumors, patients with HIF-1 alpha-positive tumors had a higher risk of recurrence and breast cancer death.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Aglaia Schiza, Viktoria Thurfjell, Axel Stenmark Tullberg, Helena Olofsson, Amanda Lindberg, Erik Holmberg, Troy Bremer, Patrick Micke, Per Karlsson, Fredrik Waernberg, Carina Strell
Summary: This study analyzed the clinical impact of tumor-infiltrating lymphocytes (TILs) in patients with ductal carcinoma in situ (DCIS). The results showed that high TILs were associated with an increased risk of ipsilateral breast events (IBEs) over five years post-surgery, particularly for HER2-negative DCIS patients. This indicates that TILs can serve as an important marker to determine the need for adjuvant therapy or potential benefits from immunotherapy in low-risk DCIS patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Andreas Josefsson, Asa Jellvert, Erik Holmberg, Klaus Brasso, Peter Meidahl Petersen, Sirpa Aaltomaa, Marjaana Luukkaa, Paul Verhagen, Ronald de Wit, Goeran Ahlgren, Ove Andren, Enrique Castellanos, Mihalj Seke, Anders Widmark, Jan-Erik Damber
Summary: This study aimed to investigate whether chemotherapy could improve progression-free survival in patients receiving endocrine therapy. The results showed that adding docetaxel could improve progression-free survival, especially in patients who had received prior local therapy.
Letter
Oncology
Martin Sjostrom, Anthony Fyles, Fei-Fei Liu, David McCready, Felix Y. Feng, Corey W. Speers, Lori J. Pierce, Erik Holmberg, Marten Ferno, Per Malmstrom, Per Karlsson
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Moa Egelberg, Tommaso De Marchi, Gyula Pekar, Lena Tran, Par-Ola Bendahl, Axel Stenmark Tullberg, Erik Holmberg, Per Karlsson, Marianne Farnebo, Fredrika Killander, Emma Nimeus
Summary: The study evaluated the prognostic and predictive role of WRAP53 protein and RNA levels in breast cancer patients. Results showed that low WRAP53 protein levels were associated with increased risk of local recurrence and breast cancer-related death. Low WRAP53 RNA levels were associated with decreased effect of radiotherapy in relation to ipsilateral breast tumor recurrence, indicating potential radioresistance.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Amalia H. Landen, Kian Chin, Aniko Kovacs, Erik Holmberg, Eva Molnar, Axel Stenmark Tullberg, Fredrik Warnberg, Per Karlsson
Summary: Tumor-infiltrating lymphocytes (TILs) can predict the response to neoadjuvant systemic therapy (NAST), while the role of mammographic density (MD) in predicting NAST response is unclear.
Article
Urology & Nephrology
Elin Axen, Johan Stranne, Marianne Mansson, Erik Holmberg, Rebecka Arnsrud Godtman
Summary: This study evaluated the long-term risk of biochemical recurrence and subsequent prognosis in a population-based cohort of patients who underwent radical prostatectomy. The results showed that the risk of biochemical recurrence persists 15 years after surgery, with the highest risk observed in patients who experienced recurrence within 2 years. The findings suggest that follow-up should continue for an extended period to allow for early detection and treatment of recurrent disease.
SCANDINAVIAN JOURNAL OF UROLOGY
(2022)
Article
Oncology
Axel Stenmark Tullberg, Henri A. J. Puttonen, Martin Sjostrom, Erik Holmberg, S. Laura Chang, Felix Y. Feng, Corey Speers, Lori J. Pierce, Dan Lundstedt, Fredrika Killander, Emma Nimeus, Aniko Kovacs, Per Karlsson
Summary: The study demonstrates that an antitumoral immune infiltrate in the primary tumor is associated with a reduced risk of breast cancer recurrence and less benefit from adjuvant radiotherapy. These findings suggest potential implications for decisions regarding postoperative radiotherapy in early breast cancer.
CLINICAL CANCER RESEARCH
(2021)
